John Lieske, MD
Nephrology · Rochester, MNNPI 1851366223
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 36.1% of the total. Among nephrology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $729.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$11K
- Alnylam Pharmaceuticals Inc.$11K
- Mirum Pharmaceuticals, Inc.$4K
- Novo Nordisk Health Care AG$3K
- Biomarin Pharmaceutical Inc.$2K
- Ultragenyx Pharmaceutical Inc.$30
- plus $2 from 1 others
Across 218 payments — averaging $11,088 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$1.4M
- Novo Nordisk AS$923K
- Novo Nordisk US Research & Development, Inc.$46K
- Novo Nordisk Health Care AG$26K
What the payments were for
- Consulting fees$17,08156%
- Speaking & faculty fees$10,17433%
- Travel & lodging$2,2327%
- Food & beverage$1,1184%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $11,074 |
| Alnylam Pharmaceuticals Inc. | 20 | $10,553 |
| Mirum Pharmaceuticals, Inc. | 1 | $3,900 |
| Novo Nordisk Health Care AG | 2 | $2,828 |
| Biomarin Pharmaceutical Inc. | 4 | $2,250 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXLUMO$8,876
How this compares
$30,637 in reported general payments places this provider in the 95th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 48 | $6,594 |
| Indapamide | 34 | $723 |
| Chlorthalidone | 20 | $384 |
| Potassium Chloride | 14 | $262 |
| Torsemide | 17 | $239 |
| Losartan Potassium | 21 | $184 |
| Hydrochlorothiazide | 19 | $123 |
| Allopurinol | 15 | $108 |
| Amlodipine Besylate | 19 | $79 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Rochester
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Nelson LeungRochester$32K
- Leticia RolonRochester$30K
- Nattawat KlomjitRochester$25K
- Ladan ZandRochester$25K
- Marie HoganRochester$19K
- Kianoush Banaei KashaniRochester$19K
- Aleksandra KuklaRochester$12K
- Vicente TorresRochester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.